Latest Industry Insights

Finalists for the New Product Award at the SLAS Europe conference showcase cutting-edge innovations in life sciences, evaluated on technical merit, commercial feasibility, originality, impact and market opportunity. Here, we take a look at the six nominees and the products competing for this year’s award.

At ELRIG’s Research and Innovation 2024 event, Technology Networks spoke with A4Cell to learn about its SPAchip® technology, which consists of intracellular silicon microchips that monitor cellular pathways in real time.

While in vitro tests and animal models can give some indication of potential drug safety issues, they do not always translate well to humans. Ignota Labs is tackling this challenge.

In this interview, Jeroen Verheyen tells us about Semarion, its SemaCyte technology and how it can help to address unmet drug screening needs.

Until recently, a lack of specialized services meant there was no definitive method for safely and effectively decontaminating plastic waste for reuse in new consumables. As a result, this waste was incinerated or diverted to landfill. The start-up company LabCycle has tackled this issue head-on, with its innovative approach to laboratory waste management. Technology Networks recently had the pleasure of speaking with LabCycle’s co-founder and chief technology officer Dr. Helen Liang, to learn more about its circular economy for laboratory plastic waste.

We interview Raffaello Sbordoni, research scientist at Revivocell, to dive deeper into how high-complexity in vitromodels are supporting pharmaceutical development and their future potential.

At ELRIG’s Research & Innovation 2024 event, Technology Networks spoke to Dr. Véronique De Conto, project leader in in vitro pharmacology at HCS Pharma, to learn more about their powerful tools for in vitro metastasis propagation.

At the European Laboratory Research and Innovation Group’s (ELRIG) Research and Innovation 2024 event, we asked a selection of start-up companies in the biotech space the same question: what are the key challenges you currently face?

We spoke with Dr. Bryan Oronsky, chief development officer at EpicentRx, to discover more about the promise of multipurpose drugs and the potential of EpicentRx’s nibrozetone (RRx-001) for several conditions.

The industry's search for alternatives to traditional preclinical drug testing methods has led to a growing interest in the potential of three-dimensional (3D) in vitro models. To delve deeper into this subject, Technology Networks spoke with Madhu Lal-Nag, chief scientific officer at InSphero, a 3D in vitro model company with a mission to “modernize drug discovery in ways that inspire researchers everywhere to reach their full potential and fuel a new era of breakthrough therapies.”